Core Viewpoint - The company, Maide Medical (688310), reported a revenue of 225 million yuan for the first three quarters of 2025, reflecting a year-on-year increase of 2.31%, with a net profit of 8.84 million yuan, up 15.82% year-on-year [3] Group 1: Financial Performance - For Q3 2025, the company achieved a single-quarter revenue of 83.64 million yuan, representing a year-on-year increase of 54.38% [3] - The net profit for Q3 2025 was 2.79 million yuan, showing a significant year-on-year increase of 224.07% [3] - The company reported a gross margin of 40.19% and a debt ratio of 29.86% [3] Group 2: Product and Market Insights - The core products contributing to revenue growth include safety infusion and blood purification intelligent equipment, along with the promotion of drug-device combination intelligent equipment [1] - The company has four production lines for contact lenses, each with an annual capacity of 18 million pieces, and is currently applying for registration of daily disposable soft contact lenses [2] - The domestic contact lens market is dominated by four major international players, but there are opportunities for domestic brands as the market evolves [2] Group 3: Future Plans and Investments - The company plans to focus on its main business development, enhance its product matrix, and invest in R&D for contact lenses, product certification, and new product development [1][2] - Future investments will also target capacity expansion and integration within the supply chain [1]

Core Viewpoint - Midea Medical's stock price has decreased by 2.59% this week, closing at 16.55 yuan, with a total market capitalization of 2.751 billion yuan [1] Company Performance - Midea Medical's stock reached a weekly high of 17.53 yuan on November 11 and a low of 16.49 yuan on November 14 [1] - The company ranks 74th out of 78 in the automation equipment sector and 4803rd out of 5165 in the overall A-share market by market capitalization [1] Upcoming Events - Midea Medical will hold a third-quarter earnings presentation on November 19, 2025, from 13:00 to 14:00 via the Shanghai Stock Exchange Roadshow Center [1] - Key personnel attending the meeting include Chairman and General Manager Lin Junhua, Secretary of the Board Lin Dong, Financial Officer Lin Junhui, and Independent Director He Tao [1] - Investors can submit questions from November 12 to November 18, 2025, before 16:00 [1]

Core Viewpoint - On November 11, 2025, Maide Medical (688310) closed at 17.13 yuan, down 1.38%, with a turnover rate of 1.48% and a trading volume of 24,600 shares, amounting to a transaction value of 42.52 million yuan [1] Trading Information Summary - On November 11, 2025, the net outflow of main funds was 7.17 million yuan, accounting for 16.86% of the total transaction value [2] - Retail investors had a net inflow of 4.98 million yuan, representing 11.72% of the total transaction value [1] Company Announcement Summary - Maide Medical will hold a third-quarter earnings briefing on November 19, 2025, from 13:00 to 14:00 via the Shanghai Stock Exchange Roadshow Center [1] - Participants in the briefing will include the Chairman and General Manager Lin Junhua, Secretary of the Board Lin Dong, Financial Officer Lin Junhui, and Independent Director He Tao [1] - Investors can submit questions from November 12 to November 18, 2025, before 16:00 through the Shanghai Stock Exchange Roadshow Center or the company's email [1]

Core Viewpoint - The company, Maide Medical (688310), is set to hold a Q3 2025 earnings presentation on November 19, 2025, to discuss its operational results and financial status for the third quarter of 2025 [1]. Group 1: Stock Performance - As of November 11, 2025, Maide Medical's stock closed at 17.13 yuan, down 1.38% from the previous trading day [1]. - The stock opened at 17.5 yuan, reached a high of 17.53 yuan, and a low of 17.06 yuan during the trading session [1]. - The total market capitalization of the company is 2.847 billion yuan, with a trading volume of 42.5197 million yuan and a turnover rate of 1.48% [1]. Group 2: Upcoming Events - The earnings presentation will take place from 13:00 to 14:00 on November 19, 2025, via the Shanghai Stock Exchange Roadshow Center [1]. - Key participants in the meeting will include the Chairman and General Manager Lin Junhua, Board Secretary Lin Dong, Financial Officer Lin Junhui, and Independent Director He Tao [1]. - Investors can submit questions from November 12 to November 18, 2025, through the Shanghai Stock Exchange Roadshow Center or the company's email [1].

Core Viewpoint - The company, Maider Medical Equipment Co., Ltd., is holding an investor briefing on November 19, 2025, to discuss its Q3 2025 financial results and address investor inquiries [2][3][4]. Group 1: Meeting Details - The investor briefing is scheduled for November 19, 2025, from 13:00 to 14:00 [5]. - The meeting will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [2][5]. - Investors can submit questions from November 12 to November 18, 2025, through the Roadshow Center website or via the company's email [2][4]. Group 2: Company Representatives - The meeting will feature key company representatives including Chairman and General Manager Mr. Lin Junhua, Secretary of the Board Mr. Lin Dong, and Financial Officer Mr. Lin Junhui [4][6]. - Independent Director Mr. He Tao will also be present, although attendance may vary due to special circumstances [4]. Group 3: Post-Meeting Information - After the investor briefing, participants can access the meeting's details and main content through the Shanghai Stock Exchange Roadshow Center [6].

Core Insights - The stock of Maide Medical (688310) closed at 17.37 yuan on November 10, 2025, with a rise of 2.24% and a trading volume of 39,500 hands, resulting in a transaction amount of 67.74 million yuan [1] Financial Performance - For the first three quarters of 2025, Maide Medical reported a main business revenue of 225 million yuan, an increase of 2.31% year-on-year, and a net profit attributable to shareholders of 8.84 million yuan, up 15.82% year-on-year [3] - In Q3 2025, the company achieved a single-quarter main business revenue of 83.64 million yuan, a year-on-year increase of 54.38%, and a net profit attributable to shareholders of 2.79 million yuan, up 224.07% year-on-year [3] - The company's gross profit margin stands at 40.19%, while the net profit margin is -2.43% [3] Market Position - Maide Medical's total market capitalization is 2.887 billion yuan, with a net asset value of 840 million yuan and a net profit of 8.84 million yuan [3] - The company has a price-to-earnings ratio (P/E) of 245.05, which is significantly higher than the industry average of 142.9 [3] - In terms of industry ranking, Maide Medical is positioned 219th in total market value and 200th in net assets among 270 companies in the specialized equipment industry [3] Capital Flow Analysis - On November 10, 2025, the net outflow of main funds was 2.65 million yuan, accounting for 3.92% of the total transaction amount, while retail investors saw a net inflow of 6.06 million yuan, representing 8.94% of the total transaction amount [1][2] - Over the past five days, the stock has experienced fluctuations in capital flow, with notable net outflows from main and speculative funds on several days [2]

证券代码：688310 证券简称：迈得医疗 公告编号：2025-046 迈得医疗工业设备股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 投资者可于 2025 年 11 月 12 日（星期三）至 11 月 18 日（星期二）16:00 前登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 （zq@maiderchina.com）进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 迈得医疗工业设备股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 19 日（星期三） 13:00-14:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 202 ...

Market Overview - The automation equipment sector experienced a decline of 1.41% on November 7, with Mai De Medical leading the losses [1] - The Shanghai Composite Index closed at 3997.56, down 0.25%, while the Shenzhen Component Index closed at 13404.06, down 0.36% [1] Stock Performance - Notable gainers in the automation equipment sector included: - Kaidi Co., Ltd. (605288) with a closing price of 95.51, up 4.78% [1] - Xinjie Electric (603416) with a closing price of 64.09, up 3.12% [1] - Haiteng Co., Ltd. (603283) with a closing price of 50.20, up 2.95% [1] - Major decliners included: - Mai De Medical (688310) with a closing price of 16.99, down 7.51% [2] - Weichuang Electric (688698) with a closing price of 77.03, down 6.40% [2] - Changfu Co., Ltd. (920396) with a closing price of 35.47, down 5.79% [2] Capital Flow - The automation equipment sector saw a net outflow of 855 million yuan from institutional investors, while retail investors contributed a net inflow of 490 million yuan [2] - The capital flow for specific stocks showed: - Kaidi Co., Ltd. (605288) had a net inflow of 38.31 million yuan from institutional investors [3] - Xinyu Laser (301021) had a net inflow of 32.02 million yuan from institutional investors [3] - However, Mai De Medical (688310) experienced a net outflow of 89.85 million yuan from retail investors [3]

Group 1 - The company held its first extraordinary general meeting of shareholders on October 30, 2025, where it approved the cancellation of the supervisory board, adjustment of the number of directors, and amendments to the Articles of Association [1][13] - The company elected Mr. Xie Yunbo as the employee representative director of the fifth board of directors during the employee representative meeting held on the same day [1][4] - The employee representative director will serve alongside the directors elected at the 2024 annual general meeting, with a term lasting until the end of the fifth board's term [1] Group 2 - The fifth board of directors' sixth meeting was also held on October 30, 2025, immediately following the extraordinary general meeting [5][7] - The meeting was attended by all eight directors, and the election of the chairman, Mr. Lin Junhua, as the legal representative of the company was approved [8][9] - The audit committee members and the convener were confirmed, with Ms. Zhang Yinghui serving as the convener [10][11] Group 3 - The extraordinary general meeting adopted several governance-related resolutions, including the revision and establishment of various governance systems [16][17] - All resolutions presented at the extraordinary general meeting were approved, with some requiring a two-thirds majority [18][19] - The meeting was witnessed by a law firm, confirming that all procedures and resolutions were in compliance with relevant laws and regulations [19]

Core Viewpoint - The recent performance of Maide Medical (688310) shows a decline in stock price and mixed financial results, with a notable increase in net profit but a significant drop in non-recurring net profit [1][3]. Stock Performance - As of October 31, 2025, Maide Medical's stock closed at 19.33 yuan, down 7.51% from the previous week [1]. - The stock reached a peak of 21.44 yuan on October 27 and a low of 18.76 yuan on October 30 [1]. - The company's current market capitalization is 3.213 billion yuan, ranking 69th out of 78 in the automation equipment sector and 4400th out of 5163 in the A-share market [1]. Shareholder Changes - As of September 30, 2025, the number of shareholders increased to 4528, up by 723 or 19.0% from June 30 [2]. - The average number of shares held per shareholder decreased from 43,700 to 36,700 shares, with an average holding value of 736,000 yuan [2]. Financial Performance - For Q3 2025, Maide Medical reported a main revenue of 225 million yuan, a year-on-year increase of 2.31% [3]. - The net profit attributable to shareholders was 8.8367 million yuan, up 15.82% year-on-year [3]. - The non-recurring net profit was -1.2785 million yuan, a significant decline of 526.58% year-on-year [3]. - In Q3 alone, the main revenue was 83.643 million yuan, reflecting a 54.38% year-on-year increase [3]. - The net profit for Q3 was 2.7916 million yuan, a substantial increase of 224.07% year-on-year [3]. - The non-recurring net profit for Q3 was 1.2364 million yuan, up 118.23% year-on-year [3]. - The company's debt ratio stands at 29.86%, with investment income of 167,600 yuan and financial expenses of -523,600 yuan, while the gross profit margin is 40.19% [3]. Company Announcements - On October 27, 2025, Maide Medical's fifth supervisory board meeting approved the Q3 report and the postponement of fundraising projects, confirming that the delay would not harm the company's or shareholders' interests [3]. - The "Annual Production of 35 Sets of Drug-Device Combination Intelligent Equipment Expansion Project" has been postponed to November 2026 due to production layout adjustments and equipment debugging, with a cumulative investment of 37.9365 million yuan, representing 59.08% of the planned investment [3]. Legal Opinions - On October 30, 2025, Maide Medical held its first extraordinary general meeting of 2025, where 13 resolutions, including changes to the supervisory board and amendments to the articles of association, were approved [4]. - The meeting had 18 attendees representing 66.7103% of the voting shares, and the legal opinion confirmed the legality and validity of the meeting procedures and resolutions [4].